Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 295
Tipo Título / Nombre Autor(es) Año
Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival Valhondo I, Pera A, Hassouneh F..., Bergua JM, Arcos MJ, Casas-Avilés I, Sánchez-García J, Serrano J, Durán E, Alonso C, Solana R, Tarazona R 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW..., Bergua Burgués JM 2025
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J..., Bergua-Burgues JM 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Martínez-Sánchez P..., Bergua JM 2025
Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry Colmenares R, Álvarez N, Barragán E, Boluda B, Larrayoz MJ..., Bergua J 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience Serrano J, Martínez-Cuadrón D, Gil C, Bernal T, Tormo M..., Bergua J 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Westin J, Tycel JP, Amitkumar M..., Bergua Burgués JM 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D..., Bergua Burgues JM 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study Boluda B, Rodríguez Viga R, Sargas C, Ayala R..., Bergua J 2025